Luca Alberici, assumed the role of Executive Vice President of Global Cell and Gene Technologies in February 2025 in addition to being the head of AGC Biologics Milan site. Luca is a value driven professional who came to AGC Biologics through the July 2020 acquisition of MolMed, a leading cell and gene therapy company. His rich educational background is complemented by more than 15 years of industry experience in roles of increasing responsibility for strategic business development and operations, licensing, project management and intellectual property for large molecule and specialty drug development and commercialization. Throughout his career, Luca has been fundamental in licensing and strategic supply agreements that drove top line results in his former position as Chief Business Officer at MolMed. In addition to practical proficiency with discovery and development for HIV and tumor therapies in his early career, Luca has extensive experience in negotiating go-to-market strategies and bringing new cell and gene therapies to market through partnerships with leading biopharmaceutical companies.

Luca earned a PhD and Masters in cellular and molecular biology from Libera Università Vita-Salute San Raffaele, in addition to a Master of Business Administration (MBA) from SDA Bocconi. He has a thorough understanding of European regulatory requirements and pricing policies, and is a published author and frequent industry speaker.